Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.

BORIS DOI
Publisher DOI
PubMed ID
30593284
Description
Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.
Date of Publication
2018-12-28
Publication Type
Article
Subject(s)
500 - Science::570 - Life sciences; biology
600 - Technology::610 - Medicine & health
600 - Technology::630 - Agriculture
Language(s)
en
Contributor(s)
Additional Credits
Institut für Tierpathologie (ITPA)
Series
Genome medicine
Publisher
BioMed Central
ISSN
1756-994X
Access(Rights)
open.access
Show full item